Report if a WHO (World Health Organization) informal consultation (jointly organized by WHO headquarters and the WHO regional office for Europe) (2009) Control and prevention of Chagas disease in Europe. Geneva, 1-74.

has been cited by the following article:

• TITLE: Cardiomyopathy protection in Chagas Disease

  AUTHORS: Jorge E. Mitelman, Luisa Gimenez

  KEYWORDS: Chagas Disease; Chronic Period without Demonstrable Pathology; Ex Indeterminate Phase; Endothelial Dysfunction; Cardiac Dysautonomia; Simvastatin; ACE (Angiotensin Converting Enzyme) Inhibitor; Muscarinic Antibody

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.3 No.7, October 14, 2013

  ABSTRACT: There is some published evidence suggesting micro vascular endothelial dysfunction and dysautonomia involvement in Chagas disease in association with cardiomyocyte changes favoring disease progression. The combined treatment between angiotensin converting enzyme (ACE) inhibitor drugs; Simvastatin, muscarinic antibody immunoadsorbent together with fungicidal drugs would open therapeutic possibilities in this disease.